Merus (NASDAQ:MRUS) Receives $85.31 Consensus Target Price from Analysts

Merus (NASDAQ:MRUS) has been given an average rating of “Buy” by the sixteen research firms that are currently covering the stock, MarketBeat Ratings reports. Fourteen research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $85.31.

A number of equities research analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating and set a $109.00 price objective on shares of Merus in a research note on Friday, March 28th. HC Wainwright restated a “buy” rating and set a $85.00 target price on shares of Merus in a research report on Monday, March 3rd. Piper Sandler assumed coverage on shares of Merus in a research report on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Merus in a report on Friday, February 7th. They set an “overweight” rating and a $91.00 price objective for the company. Finally, Bank of America cut their target price on shares of Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a report on Monday, March 10th.

Institutional Investors Weigh In On Merus

A number of hedge funds and other institutional investors have recently bought and sold shares of MRUS. Wells Fargo & Company MN boosted its position in Merus by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 300 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in Merus by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company’s stock worth $1,921,000 after purchasing an additional 331 shares during the last quarter. Deutsche Bank AG grew its position in Merus by 0.4% in the fourth quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company’s stock valued at $4,754,000 after purchasing an additional 416 shares in the last quarter. Gordian Capital Singapore Pte Ltd grew its position in Merus by 10.4% in the third quarter. Gordian Capital Singapore Pte Ltd now owns 5,000 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 470 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Merus by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 52,636 shares of the biotechnology company’s stock valued at $2,213,000 after buying an additional 540 shares during the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Trading Up 13.4 %

Shares of NASDAQ MRUS opened at $39.56 on Monday. Merus has a 1 year low of $33.19 and a 1 year high of $61.61. The firm’s 50-day moving average is $43.64 and its 200-day moving average is $45.35. The firm has a market capitalization of $2.73 billion, a PE ratio of -10.02 and a beta of 1.02.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.48. The firm had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, equities research analysts anticipate that Merus will post -3.85 earnings per share for the current fiscal year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.